News Pfizer cues up vitiligo filing for Litfulo after phase 3 win Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
